ID
99
Description
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Keywords
Versions (4)
- 11/21/11 11/21/11 -
- 3/27/14 3/27/14 - Martin Dugas
- 9/17/21 9/17/21 -
- 9/27/21 9/27/21 - Sarah Riepenhausen
Uploaded on
November 21, 2011
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Eligibility
- StudyEvent: Eligibility
Description
Ausschlusskriterien
Alias
- NCI Metathesaurus CUI
- C0680251
Description
Prior treatment
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C1522449
- NCI Metathesaurus CUI
- C0949266
Description
Bone marrow
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C0005953
Description
Liver function
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C0232744
Description
Renal function
Data type
boolean
Alias
- NCI Metathesaurus CUI
- C0341697
Similar models
Eligibility
- StudyEvent: Eligibility
C0949266 (NCI Metathesaurus CUI)